Fig. 2: Subgroup analyses of confirmed objective response rate by blinded independent central review.
From: Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
Odds ratios (center) are presented with 95% CI (error bars). EC+mFOLFOX6, encorafenib and cetuximab plus oxaliplatin, leucovorin and 5-FU. aPercentages were calculated based on the number of participants in the objective response rate subset of all randomized patients in each treatment group. bObjective response rate calculated based on the number of participants in the objective response rate subset of all randomized patients within each treatment group and subgroup. The odds ratio was estimated using the Mantel–Haenszel method. The exact CI was calculated.
